SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants
- Tea, F.
- Stella, A.O.
- Aggarwal, A.
- Darley, D.R.
- Pilli, D.
- Vitale, D.
- Merheb, V.
- Lee, F.X.Z.
- Cunningham, P.
- Walker, G.J.
- Fichter, C.
- Brown, D.A.
- Rawlinson, W.D.
- Isaacs, S.R.
- Mathivanan, V.
- Hoffmann, M.
- Pöhlman, S.
- Mazigi, O.
- Christ, D.
- Rockett, R.J.
- Sintchenko, V.
- Hoad, V.C.
- Irving, D.O.
- Dore, G.J.
- Gosbell, I.B.
- Kelleher, A.D.
- Matthews, G.V.
- Brilot, F.
- Turville, S.G.
DOIAbstract
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) antibody neutralization response and its evasion by emerging viral variants and variant of concern (VOC) are unknown, but critical to understand reinfection risk and breakthrough infection following vaccination. Antibody immunoreactivity against SARS-CoV-2 antigens and Spike variants, inhibition of Spike-driven virus–cell fusion, and infectious SARS-CoV-2 neutralization were characterized in 807 serial samples from 233 reverse transcription polymerase chain reaction (RT-PCR)–confirmed Coronavirus Disease 2019 (COVID-19) individuals with detailed demographics and followed up to 7 months. A broad and sustained polyantigenic immunoreactivity against SARS-CoV-2 Spike, Membrane, an...
Add to ORKG